We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MAP gets US complete response letter for migraine drug

News

Executive Summary

MAP Pharmaceuticals said it will continue to pursue approval of Levadex (dihydroergotamine) inhalation aerosol for the acute treatment of migraine in adults and plans to request a meeting with the US FDA following a complete response letter (CRL) from the agency.